Recent Advances in Allogeneic CAR-T Cells
In recent decades, great advances have been made in the field of tumor treatment. Especially, cell-based therapy targeting tumor associated antigen (TAA) has developed tremendously. T cells were engineered to have the ability to attack tumor cells by generating CAR constructs consisting of genes enc...
Main Authors: | Dong Wook Kim, Je-Yoel Cho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/2/263 |
Similar Items
-
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
by: Kenneth J. Caldwell, et al.
Published: (2021-01-01) -
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
by: Jun Liu, et al.
Published: (2017-01-01) -
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
by: Ariadna Bartoló-Ibars, et al.
Published: (2021-09-01) -
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
by: Darel Martínez Bedoya, et al.
Published: (2021-03-01) -
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
by: Miriam Marangon, et al.
Published: (2021-01-01)